CEPI Global Vaccines Launch May Augur Creation Of Credible Davos Deal
Executive Summary
If in five years' time the newly launched CEPI coalition successfully produces DNA and RNA-based vaccines for use against future epidemics, then the high-profile Davos forum will really have something to crow about.
You may also be interested in...
Themis Bioscience Reaps Bill Gates' Backed CEPI Funding For Lassa Fever And MERS Vaccines
Plans to have candidate vaccines ready for testing against infectious diseases during an evolving epidemic have taken a step forward with the announcement of a partnership between CEPI, the global fund supported by governments and philanthropists, and the vaccine-focused European biotech, Themis Bioscience.
Best Of BIO: Policy & Regulatory Updates From BIO 2017
Antibiotic incentives, vaccine strategies, drug pricing, patent updates and more hot topics from the Biotechnology Innovation Organization's recent annual conference.
BIO Notebook, Day 2: Deal Insights, A Payer Perspective And EMA Rumors
In the spirit of the BIO International Convention's partnering focus, Scrip covered a dealmaker survey and spoke to Bayer about some of its business development priorities on day two of the annual convention. We also report on a payer perspective, post-Brexit EMA rumors and investments in vaccines.